Close Menu

sequencing-based diagnostics

The US Court of Appeals for the Federal Circuit sent the case, which had been thrown out in December 2018, back to the trial court.

North Dakota-based MedScan Laboratory will collect patient samples and extract RNA for Fulgent's new NGS-based clinical assay for SARS-CoV-2.

The insurer will cover testing at the Rady Children's Institute for Genomic Medicine for children in intensive care with unexplained medical conditions.

The firm has opened a $10 million Series A financing round that it expects to close in late summer to support running clinical studies for its assay.

The clearances pave the way to clinical applications for three of MGI's instruments but the BGI subsidiary faces legal challenges from Illumina in Europe and the US.

Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.

The firm said it will use the funding to invest in research and development that will improve upon its deep shotgun metagenomic sequencing technology.

The acquisition will allow the firms to provide annotated biospecimens, as well as sequencing, bioinformatics, and lab services to hospitals and clinicians.

Centogene said it will conduct molecular diagnostic testing using deletion/duplication analysis and full-length sequencing of the DMD gene.

New funding will support assay development and lab space to offer test services, and ultimately a test kit using the firm's resistance database.

Pages